ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
26 Abril 2024 - 6:35PM
Business Wire
GanNA founders Carolyn Bertozzi, Ph.D., and
Richard D. Cummings, Ph.D., to serve as advisors to ReNAgade
Additional investment strengthens ReNAgade’s
delivery platform with unique conjugation platform based on novel
glycobiology
ReNAgade Therapeutics, a company unlocking the limitless
potential for RNA medicines, today announced its ongoing commitment
to exploring the therapeutic opportunity of glycobiology through
support for ongoing research at GanNA Bio, and the integration of
key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA
founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D,
will now serve as advisors to ReNAgade.
“ReNAgade will continue to benefit tremendously from GanNA’s
promising work in developing extra-hepatic delivery technology that
helps expand the breadth and potential of our own RNA medicines,”
said Brian Goodman, Co-founder of ReNAgade. “Delivery is
foundational to ReNAgade’s mission to overcome the current
limitations of RNA medicines. We believe the technology developed
within GanNA will help further solidify ReNAgade’s leadership
position as we continue advancing our unique, integrated
therapeutic platform.”
Formed in 2021 and invested in by ReNAgade, GanNA Bio harnesses
novel glycobiology to enable extra-hepatic RNA delivery based on
pioneering research licensed from Stanford University, Boston
Children’s Hospital, and Beth Israel Deaconess Medical Center. This
research was developed in the labs of Carolyn Bertozzi, Ph.D.,
winner of the 2022 Nobel Prize in Chemistry and Professor of
Chemistry in the Stanford School of Humanities and Sciences; Ryan
A. Flynn, M.D., Ph.D., Assistant Professor at Boston Children’s
Hospital; and Richard D. Cummings, Ph.D., S. Daniel Abraham
Professor of Surgery at Beth Israel Deaconess Medical Center, and
led by Namita Bisaria, Ph.D, M.B.A., a serial entrepreneur in the
RNA therapeutics field. Its platform, based on new advances in
glycobiology and synthesis, uses cell-specific glycans to develop
next-generation conjugates and unlock the delivery of short and
long stranded RNA medicines.
“The combination of GanNA’s innovative glycobiology-based
targeting strategy with ReNAgade’s experience in the development of
RNA medicines will be a powerful combination for the benefit of
patients,” said Dr. Bertozzi. "The progress in glycoRNA science
from our seminal publication in the journal Cell is moving fast,
and integration with ReNAgade’s pipeline will strengthen our
position to develop a broad portfolio of cell-specific delivery
systems, leveraging the latest developments in glycobiology in
order to expand the array of addressable diseases for RNA
medicines. Glycobiology-based RNA medicines represent a new
frontier, and it is rewarding to see the possibilities of ReNAgade
developing these for clinical use.”
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to
treat disease anywhere in the body. We combine our novel RNA
delivery platforms with a comprehensive RNA platform allowing for
an all-RNA system for coding, editing, and gene insertion to
develop new medicines.
To accelerate the future of medicine, we bring together a team
with deep RNA and delivery expertise to develop paradigm-shifting
RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and
its leadership, visit www.renagadetx.com
About GanNA Bio
GanNA was created by Drs. Flynn and Bisaria, and invested by
ReNAgade in 2021 following a sponsored research agreement in the
lab of Dr. Flynn. The mission is to explore the potential of novel
glycobiology therapies following the pioneering work at Stanford
University by Drs. Flynn and Bertozzi on glycoRNA. The GanNA Bio
Scientific Advisory Board included Drs. Bertozzi, Cummings, Flynn,
and ReNAgade CSO, Pete Smith.
University Conflict of Interest Disclosure
Drs. Bertozzi, Cummings and Flynn consult for ReNAgade
Therapeutics.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240426251202/en/
Investor Relations: Emily Brabbit, Argot Partners (212)
600-1902 renagade@argotpartners.com Media Relations: Sarah
Sutton, Argot Partners (212) 600-1902
renagade@argotpartners.com